The 13-fold variation in rates of asymptomatic PSA-detected prostate cancer between practices speaks to the ongoing lack of clarity regarding prostate cancer screening practice in the UK.23 Evidence from this study and others consistently show that men from more deprived areas are less likely to undergo PSA testing and more likely to be diagnosed with late-stage prostate cancer.6,24 Patient factors were found to have a profound impact on PSA testing and are, therefore, likely to play a role in driving prostate cancer inequalities. The gene discussed is KLK3; the disease is prostate carcinoma.